Sam Brusco, Associate Editor04.19.22
Carlsmed, developer of the U.S. Food and Drug Administration (FDA)-cleared aprevo personalized spine fusion devices, closed a $30 million Series B funding round led by multi-stage investment firm B Capital Group.
The company will use the funds to ramp commercialization of aprevo. The company uses patient data and digital technologies to create devices that align with the surgeon’s goals for each patient.
“Traditionally, patients undergoing spinal surgery are at risk for postoperative complications and revision surgery. Our goal is for aprevo to be the last spinal surgery a patient will ever need,” Mike Cordonnier, CEO of Carlsmed told the press. “Unlike conventional implants that are mass produced in stock shapes and sizes, each aprevo device is designed for a specific patient, with spinal alignment correction built into the device.”
Carlsmed also appointed two new board members: B Capital Group general partner and head of healthcare Robert Mitterdorf, MD, MBA as well as B Capital Group senior principal of healthcare Widya Mulyasamita, Ph.D., will join the company’s board.
“We are pleased to support the Carlsmed team in the transformation of spine surgery, enabled with artificial intelligence, to produce patient and surgeon specific implants,” said Dr. Mittendorff. “The potential for the Carlsmed platform to improve both surgical workflow and patient outcomes is substantial, and the team leading this innovation is second to none.”
“Carlsmed represents the future of surgery, where machine learning and artificial intelligence technologies enable improved outcomes for patients,” added Dr. Mulyasasmita. “The aprevo devices are unique in that they deliver personalized medicine that is simple for surgeons to adopt and scalable as a business.”
The company will use the funds to ramp commercialization of aprevo. The company uses patient data and digital technologies to create devices that align with the surgeon’s goals for each patient.
“Traditionally, patients undergoing spinal surgery are at risk for postoperative complications and revision surgery. Our goal is for aprevo to be the last spinal surgery a patient will ever need,” Mike Cordonnier, CEO of Carlsmed told the press. “Unlike conventional implants that are mass produced in stock shapes and sizes, each aprevo device is designed for a specific patient, with spinal alignment correction built into the device.”
Carlsmed also appointed two new board members: B Capital Group general partner and head of healthcare Robert Mitterdorf, MD, MBA as well as B Capital Group senior principal of healthcare Widya Mulyasamita, Ph.D., will join the company’s board.
“We are pleased to support the Carlsmed team in the transformation of spine surgery, enabled with artificial intelligence, to produce patient and surgeon specific implants,” said Dr. Mittendorff. “The potential for the Carlsmed platform to improve both surgical workflow and patient outcomes is substantial, and the team leading this innovation is second to none.”
“Carlsmed represents the future of surgery, where machine learning and artificial intelligence technologies enable improved outcomes for patients,” added Dr. Mulyasasmita. “The aprevo devices are unique in that they deliver personalized medicine that is simple for surgeons to adopt and scalable as a business.”